Form 4: Sarepta Therapeutics Director Richard Barry Reports Acquisition of Shares and Stock Options

Director Richard Barry reported acquiring shares and stock options in Sarepta Therapeutics on March 10, 2025.

Summary

• Richard Barry, a director of Sarepta Therapeutics, reported changes in beneficial ownership on March 11, 2025.
• On March 10, 2025, Barry acquired 2,383 shares of common stock through restricted stock units (RSUs) at a price of $0, which will vest on March 10, 2026.
• Barry also acquired 4,792 stock options with an exercise price of $99.69, exercisable from March 10, 2026, and expiring on March 10, 2035.
• Following these transactions, Barry directly owns 4,792 derivative securities and 2,934,071 shares of common stock, and indirectly owns 240,000 shares via a trust and 10,000 shares via an LLC.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of shares and options could be seen as slightly positive, but it's not a major event.

Positives

• The acquisition of shares and stock options by a director could be interpreted as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The reported transactions provide shareholders with insight into the actions of a company director.

Key Dates